MK-0518

Medical Advocates
Raltegravir (Isentress/MK-0518)

Conference Citations

19th CROI
6th IAS Conference
18th CROI
XVIII International AIDS Conference
17th CROI
5th IAS Conference
16th CROI
Ninth Int Congress on Drug Therapy in HIV Infection
More Conference Citationsl

Raltegravir Main Page Main New/Newsworthy Home Page

Last Update: March 18, 2012
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

19th CROI

POSTER
Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age: Interim Results from IMPAACT P1066
S Spector , E Acosta, N Zheng, et al
PDF Poster Abstract

POSTER
Phenotypic Susceptibility to Raltegravir and Genetic Pathways to INI Resistance in HIV-2
R Smith, D Raugi, C Pan, et al
PDF Poster Abstract
Three Phases of Plasma HIV-1 RNA Decay Revealed by Single-copy Assay in ARV-naïve Patients Initiating ART with Raltegravir, Tenofovir, and Emtricitabine: ACTG A5248
A Andrade, S Rosenkranz, A Cillo, et al
Abstract
Differences in the Kinetics and Mg Dependency of Binding of First, Second, and Third Generation HIV INSTI to Wild Type vs Raltegravir-resistant G140S/Q148H IN
Z Lin, D Langley, B Terry, et al
Abstract

POSTER
The Influence of the HCV Protease Inhibitor Bocepravir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir
C de Kanter, M Blonk, A Colbers, et al
PDF Poster Abstract

POSTER
Association between Markers of Immune Activation, Inflammation, Coagulation, and Virologic Failure in ACTG A5262: A Single-arm Study of Darunavir/ritonavir Plus Raltegravir in Treatment-naïve HIV-1+ Patients
C Wilson, R Matining, J Eron, et al
PDF Poster Abstrac

POSTER
Broad-spectrum Anti-HIV Activity of GRFT and Synergy with the Antiviral Drugs Maraviroc, Tenofovir, and Raltegravir
G Férir, K Palmer, D Schols. et al
PDF Poster Abstract
Effect of Raltegravir Intensification on Endothelial Function in Treated HIV Infection
Priscilla Hsue, R Scherzer, Y Wu, et al
A WEEK-IN REVIEW FEATURED REPORT
POSTER
Decrease in Inflammatory and Coagulation Biomarkers in HIV⁺ Patients after Switching from Enfuvirtide to Raltegravir:
The Randomized ANRS 138 EASIER Trial
E Silva , I Charreau, B Gourmel, et al
PDF Poster Abstract

POSTER
Improved Low BMD and Bone Turnover Markers with Switch from Tenofovir to Raltegravir in Virologically Suppressed HIV-1⁺ Adults at 48 Weeks: The TROP Study
M Bloch, W Tong, J Hoy, et al
PDF Poster Abstract
The Pharmacokinetic Interaction between Raltegravir and Rifapentine in Healthy Volunteers
M Weiner, C Peloquin, M Engle, et al
Abstract
Effect of Maraviroc Intensification on the Decay of HIV-1 DNA in PBMC and Residual Viremia of Recently Infected Patients Initiating Treatment with Raltegravir plus Tenofovir/Emtricitabine: A 48-Week Randomized Study
M Puertas, J Llibre, M Ballestero, et al
Abstract
The Intracellular Disposition of Raltegravir Is Dependent on P-gp (ABCB1) Activity and Is Significantly Reduced in Primary CD4⁺ P-gp^high T Cells
G Minuesa, I Erkizia, C Arimany-Nardi, et al
Pharmacogenetics of Raltegravir Penetration into CSF and PBMC
Dohnson, D Sutherland, D Richardson, et al
Abstract
POSTER
Raltegravir Therapy Induces Rapid Decrease in Immune Activation, PD1 Expression, and Gut Microbial Translocation with Increased Recovery of Central Memory CD4 T Cells in Treatment-naïve Patients with Chronic HIV Infection
S Pallikkuth , M Fischl, S Pahwa, et al
PDF Poster Abstract

POSTER
Impact of Raltegravir on HIV-1 RNA and DNA Species following Initiation of ART
C Stephan, H-M Baldau, A Haberl, et al
PDF Poster Abstract
Stable HIV-1 Integrase Diversity during Initial HIV-1 RNA Decay Suggests Complete Blockade of Plasma HIV-1 Replication by Effective Raltegravir-containing Salvage Therapy
M Noguera-Julian, M Casadellà, C Pou, et al
Abstract
POSTER
APOBEC3G Synergistically Augments HIV-1 Integrase Inhibition by Raltegravir
C Song, J Donahue, R D’Aquila
PDF Poster Abstract

POSTER
Multiple-dose Pharmacokinetics of Raltegravir in Patients Co-infected with HIV/HCV with and without Advanced (Child-Pugh grade C) Hepatic Cirrhosis
B Hernandez-Novoa , A Moreno, M Perez-Elias, et al
PDF Poster Abstract

POSTER
48-Week Raltegravir Intensification Shows Differing Effects on CD8 and CD4 T Cells in Treated HIV+ Individuals with Poor CD4 T Cell Recovery
M Massanella, E Negredo, M Buzon, et al
PDF Poster Abstract

POSTER
Decrease in Inflammatory and Coagulation Biomarkers in HIV⁺ Patients after Switching from Enfuvirtide to Raltegravir: The Randomized ANRS 138 EASIER Trial
E Silva, I Charreau, B Gourmel, et al
PDF Poster Abstract

6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

A WEEK-IN-REVIEW FEATURED REPORT
POWERPOINT POSTER PRESENTATION
Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive
HIV-1-infected patients; final analysis of protocol 004
E. Gotuzzo, B.-Y. Nguyen, M. Markowitz, et al

POSTER
Persistence of antiretroviral regimens including raltegravir, maraviroc, darunavir and/or etravirine in clinical practice
I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
Poster     Abstract
POSTER
Prevalence of primary resistance mutations to raltegravir in HIV naïve and pre-treated patients with B and non-B
subtypes
C. Gutiérrez, C. Page, B. Hernández-Novoa, et al
Poster     Abstract

POSTER
Virological response to treatment in patient who start raltegravir in combination with newer agents in current
clinical practice
L.E. Weimer, M. Floridia, R. Bucciardini, et al
Poster     Abstract

POSTER
Twelve months of raltegravir administration do not induce or exacerbate autoimmunity in HIV-positive patients
S. Baroncelli, M.C. Galluzzo, A. Degli Antoni, et al
Poster     Abstract

POSTER
Metabolic profile in a cohort of HIV-1 positive patients treated with RAL-based therapy
C. Martinelli, P. Corsi, et al
Poster     Abstract

POSTER
Raltegravir intensification in HIV-infected patients with immune discordant response to HAART
C. Cesar, P. Patterson, M.L. Vázquez, et al
Poster     Abstract

POSTER
An approach to the management of children failing second-line antiretroviral therapy (ART) at the Botswana-Baylor
Children's Clinical Centre of Excellence (COE) and decentralized ART sites in Botswana
M. Tolle, A. Gomila, H. Jibril, et al
Poster     Abstract

Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive
HIV-1-infected patients; final analysis of protocol 004
E. Gotuzzo, B.-Y. Nguyen, M. Markowitz, et al
Abstract

Phenotypic resistance of HIV-2 variants to the integrase inhibitor raltegravir
R.A. Smith, D.N. Raugi, N.B. Kiviat, et al
Abstract

Effects of HIV integrase polymorphisms on raltegravir-resistance susceptibility
H. Suzuki, M. Maejima, J. Hattori, et al
Abstract

Effects of raltegravir (RAL)-including regimen on the B cells subsets redistribution in a cohort of multi-drug resistant
HIV-1 infected patients
S. Pensieroso, L. Galli, M. Tolazzi, et al
Abstract

Reconstitution patterns of resident and circulating Gut-homing CD4+ T cells in HIV-1 infected individuals during
antiretroviral therapy initiated in either primary or chronic infection
K. Koelsch1, J. Zaunders, N. Seddiki, et al
Abstract

Impact of raltegravir pressure on the selection of HIV-1 envelope sequences in vitro
S. Harada, T. Ishikawa, A. Hamaji, et al
Abstract

Raltegravir as replacement for PI- or NNRTI-based ART in HIV-infected women with lipohypertrophy: the women,
integrase, and fat accumulation trial
J. Lake, G.A. McComsey, T. Hulgan, et al
Abstract

Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir
R.D. Bruce, D. Moody, D. Chodkowski, et al
Abstract

Virological impact of introducing darunavir and raltegravir for multiexperienced HIV-1-infected patients in Brazil
R. Hallal, H. Bernal1 R. Kuchenbecker, et al
Abstract
Raltegravir resistance in antiretroviral therapy naïve HIV-1 Subtype non-B infected patients: the SnoB study
S. Sierra, N. Lübke, S. Reuter, et al
Abstract
Raltegravir (RAL) and nevirapine (NVP) dual therapy maintains virologic suppression in HIV-infected
HAART-treated patients: 48-week results of a pilot study
V. Reliquet, C. Chirouze, P. Muret, et al
Abstract

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI,
NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study
S. Di Giambenedetto, M. Fabbiani, M. Colafigli, et al
Abstract

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA
in gut associated lymphoid tissue (GALT): a randomized, placebo controlled trial
C. Kovacs, J. Brunetta, T.-W. Chun, et al
Abstract

Proviral HIV changes in multi-drug resistant patients receiving raltegravir-including and nucleoside reverse transcriptase
inhibitor-sparing regimens
N. Gianotti, M. Malnati, L. Galli A., et al
Abstract

Effect of intensification with raltegravir on HIV-1 latently infected CD4+ memory T cells
C. Gutiérrez, L. Díaz, A. Vallejo, et al
Abstract

Ex vivo modeling of viral reactivation strategies in successfully treated subjects
R. Fromentin, S. DaFonseca, C. Vandergeeten, N. Chomont

Abstract

18th CROI

POSTER
Intracellular Pharmacokinetics and Drug Interaction between DRV/r Once Daily and RAL Once and Twice Daily in
HIV-infected Individuals
A Jackson, D Back, S Khoo, et al
PDF Poster Abstract
POSTER
Long-term Follow-up of Patients Receiving RAL, ETV, and DRV/r in the ANRS 139 TRIO Trial
C Fagard, D Descamps, C Colin, et al
PDF Poster Abstract
POSTER
Reduction of Chronic Inflammation Occurs in Selected Patients with RAL Intensification
K Lichtenstein, C Armon, R Harbeckm et al
PDF Poster Abstract
POSTER
ACTG A5249s: Time to Onset of First-phase Viral Decay in Antiretroviral-naïve Patients Treated with RAL and FTC/TDF
A Andrade, S Rosenkranz, D Lu, et al
PDF Poster Abstract
POSTER
HIV RNA and HIV DNA in an Integrase Inhibitor-containing Regimen in Treatment-naïve Patients
J Murray K McBride, L Gelgor, et al
PDF Poster Abstract
POSTER
Influence of pH on Transcellular Permeability of RAL: Unravelling the Interaction with Antacids and Food
D Moss, M Murphy, M Siccardi, , et al
PDF Poster Abstract
POSTER
Pharmacokinetics of Once-daily RAL/ATV in HIV-1-infected Patients
A Jansen, A Colbers, A van der Ven, et al
PDF Poster Abstract
POSTER
A Pilot Study of the Effect of RAL Intensification on CNS Immunoactivation in Virally Suppressed Subjects
R Price, E Lee, I Leppla, et al
PDF Poster Abstract
POSTER
48 week results of a pilot randomized study of an nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen
of raltegravir (RAL) + lopinavir/ritonavir (LPV/r) versus efavirenz/tenofovir disoproxil fumarate /emtricitabine
(EFV/TDF/FTC) in Antiretroviral-Naive Patients: CCTG 589
V. Bowman, G. Rieg, S. Jain, et al
PDF Poster Abstract
RAL in Combination with Tenofovir and Emtricitabine during Primary and Chronic HIV Infection: Impact on HIV RNA and DNA
in Peripheral Blood and Gut Mucosal Tissue
K Koelsch, C Boesecke, P Fahey, et al
Abstract
Ultra-deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART
M Buzon, F Codoñer, C Pou, et al
Abstract
Dynamics of CD8 T Cell Activation during RAL Intensification and after Its Discontinuation in HAART-suppressed Subjects
M Massanella, M Buzon, A Esteve, et al
Abstract
Integrase Mutation T97A and Resistance to RAL
S Reigadas, B Masquelier, C Calmels, et al
Abstract
Identification of Alternative Amino Acid Substitutions at HIV-1 Integrase Codon 143 that Confer Reduced Susceptibility to RAL
W Huang, S Fransen, A Frantzell,C Petropoulos
Abstract
Mutations of HIV-2 Integrase at Positions 140, 148, 155, but Not 143 Play the Same Role in Resistance to RAL than for HIV-1
O Delelis, X-J Ni, C Charpentier, et al
Abstract

XVIII International AIDS Conference

POSTER
Drug-resistant genotyping to guide selection of etravirine, darunavir and raltegravir in salvage therapy f
or multi-drug-resistant cases improves outcomes
N. Miyazaki, S. Matsushita, T. Fujii, et al
PDF Poster     Abstract

POSTER
Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in clinical practice
I. Castillo Romera, A. A Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster     Abstract

POSTER
Raltegravir and enfuvirtide as a "bridge" antiretroviral therapy in kidney-transplanted patients with
HIV infection receiving everolimus and low-dose cyclosporine: a case-control study
S. Cocchi, D. Bonucchi, R. Pulizzi, et al
PDF Poster     Abstract

POSTER
Impact of raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with
undetectable viremia on HAART
C. Garrido, N. Rallon, N. Zahonero, M. et al
PDF Poster     Abstract

POSTER
Impact of the HIV-1 integrase flexibility on the alternative resistance pathways to raltegravir
S. Abdel-Azeim, E. Laine, D. Perahia, et al
PDF Poster     Abstract

POSTER
Immunological benefit of raltegravir when used as part of switch strategies
C. Garrido, L. Anta, N. Zahonero, et al
PDF Poster     Abstract

POSTER
Early viral response in a cohort of heavily ARV-experienced patients receiving a salvage regimen
recommended by a national advisory board in Mexico
Y. Vargas-Infante, J. Andrade-Villanueva, J. Sierra-Mader ,et al
PDF Poster    Abstract

POSTER
Raltegravir-based-HAART and lymphoma chemotherapy
S. Marcotte, M. Laroche, I. Turcotte, et al
PDF Poster    Abstract

The impact of raltegravir on TCR rearrangement processes may lead to reduced thymic output.
A sub-study of the ANRS 138 easier trial
S. Rozlan, C. Codron, J. Dutrieux1,et al
Abstract

Raltegravir pharmacokinetics (PK) in treatment naïve patients is not influenced by race: PK results
from the early therapy in African-Americans (AA) living with HIV (REAL) study
D. Wohl, J. Dumond, S. Blevins, et al
Abstract

Intraparticular drug transfer results in high level of raltegravir (RAL) activity
H. Walter, K. Tennert, C. Paatz, S. Wittmann
Abstract

Incidence of emtricitabine, tenofovir, raltegravir, and lopinavir resistance following twice-daily
(BID) lopinavir/ritonavir (LPV/r) in combination with once-daily (QD) emtricitabine/tenofovir (FTC/TDF)
r twice daily raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects: 48-week results of a 96-week
randomized trial (study M10-336)
A. Lawal, L. Maroldo, R. Rivero, M. et al
Abstract

Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir
in Rio de Janeiro, Brazil: a six month follow-up
C.P.B. Passaes, M.L. Guimarães, S.W. Cardoso, et al
Abstract

Transmission of integrase strand-transfer inhibitor multi-drug resistant HIV: case report and
natural history of response to raltegravir-containing antiretroviral therapy
B. Young, S. Fransen, K. Greenberg, et al
Abstract

Genotypic resistance to darunavir, tipranavir and etravirine in patients with failure to two or more
ARV combinations in Mexico
E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al
Abstract

Hard rescue: prospective study of effectiveness and safety of new drugs (Darunavir-DRV,
Etravirina-ETR, Raltegravir-RTG andMaraviroc-MVC) in the last four years (2006-2009)
H. Azkune Galparsoro, J.A. Iribarren Loyarte, M.J. Aramburu Bengoechea, M.A
Abstract

Raltegravir in the prevention of mother to child transmission of HIV: high concentrations
demonstrated in newborns
M. Rosenvinge, D. McKeown, I. Cormack, et al
Abstract

In vivo synergistic activity of maraviroc and raltegravir in the reduction of HIV proviral burden in
circulating reservoirs
C. Tommasi, E. Nicastri, I. Abbate, et al
Abstract

Retrospective review of raltegravir in an urban HIV clinic
J. Scott, R. Bolan
Abstract

Safety (specially renal) and antiretroviral activity or raltegravir-based HAART in HIV-subjects
after solid organ transplantation
A. Moreno-Zamora, M.J. Pérez-Elías, J.L. Casado, et al
Abstract

In vivo evolution of resistance associated mutations at Raltegravir failure, and after therapy interruption:
comparative genotypic and phenotypic analyses
F. Canducci, E. Ceresola, B. Barda, et al
Abstract

Safety (specially renal) and antiretroviral activity or raltegravir-based HAART in HIV-subjects after
solid organ transplantation
A. Moreno-Zamora, M.J. Pérez-Elías, J.L. Casado, et al
Abstract

Simplification of antiretroviral therapy by switching from ritonavir-boosted protease inhibitors to raltegravir
in virologically suppressed HIV-1-infected patients (SPIRAL): a randomised open-label trial
E. Martinez, M. Larrousse, J.M. Llibre, et al
Abstract

Simplification from protease inhibitors to once or twice daily raltegravir: the ODIS trial
E. Vispo, P. Barreiro, I. Maida, et al
Abstract

A pilot study to assess the immunological response when raltegravir is added to a virologically
suppressed HAART regimen
K. Lichtenstein, R. Harbeck, V. Nagabhushanam, et al
Abstract

Pharmacokinetics (PK) of raltegravir (RAL) in the blood plasma (BP) and genital tract (GT) in
HIV+ and HIV- women
K. Patterson, H. Prince, N. White, et al
Abstract

17th CROI

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Metabolic Profiles and Body Composition Changes in Treatment-Naive HIV-Infected
Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each
bedtime Combination Therapy: 96-Week Follow-Up
E DeJesus, C Cohen, J Lennox. et al
PDF Poster Abstract
POSTER
Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART
in Treatment-naive HIV-1-infected Patients
E Gotuzzo, B-Y Nguyen, M Markowitz, et al
PDF Poster Abstract
POSTER
Pharmacokinetic (PK), Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to 11 Years
from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth
S Nachman, P Samson, E Acosta, et al
PDF Poster Abstract
POSTER
Sustained Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK Studies and
Exploratory Analysis of Late Outcomes based on Early Virologic Responses
J Eron, D Cooper, R Steigbigel. et al
PDF Poster Abstract
POSTER
Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory
Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen:
DIVA 01 Study
C Clavel, L Mandelbrot, A-G Marcelin, , et al
PDF Poster Abstract
POSTER
Stage-dependent Inhibition of HIV-1 in vitro and Implications for Raltegravir
D Donahue, R Sloan, B Kuhl, et al
PDF Poster Abstract
POSTER
Raltegravir is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter
Pgp But Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2
D Moss, W-S Kwan, N Liptrott, et al
PDF Poster Abstract
POSTER
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers
S Bonora, A D’Avolio, M Simiele, et al'
PDF Poster Abstract
POSTER
Intracellular and Plasma Pharmacokinetics of Raltegravir in HIV-Infected Patients
A Fayet-Mello, T Buclin, C Franc, et al
PDF Poster Abstract
POSTER
No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing
Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS
138 Trial
Ce Laugerre, I Charreau, J Braun, et al
PDF Poster Abstract
POSTER
Short -Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL
Resistance during Subsequent Combination Therapy: Analysis of Samples from Protocol 004
M Miller, R Barnard, M Witmer, et al
PDF Poster Abstract
POSTER
Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
J Rockstroh, H Teppler, J Zhao, et al
PDF Poster Abstract
POSTER
Raltegravir Genetic Resistance Patterns in HIV-2 Infected Patients Failing Raltegravir-containing
Regimen
B Roqueber, S Matheron, A Benard, et al
PDF Poster Abstract
POSTER
Bulk and Clonal Resistance Analyses in Highly Experienced Patients Failing Raltegravir, Etravirine, and Darunavir/ritonavir Containing Regimen (ANRS 139 TRIO Trial)
B Roquebert, C Colin, A-M Taburet, et al
PDF Poster Abstract
POSTER
Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir When Combined in
Treatment-experienced Patients: A Substudy of the ANRS 139 TRIO Trial
A Barrail-Tran, Y Yazdanpanah, C Fagard, et al
PDF Poster Abstract
HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of
HAART-suppressed Patients
M J Buzon, M Massanella, J Llibre, et al
Abstract
Primary Mutations Associated with Resistance to Raltegravir are not Detectable by |
Pyrosequencing in Integrase-Inhibitors Naive Patients
F Ceccherini-Silberstein, D Armenia, R D’Arrigo, et al
Abstract
Comparison of Raltegravir Susceptible and Resistant Viruses Define the Contribution of
Secondary Mutations to Reductions in Raltegravir Susceptibility
S Fransen, A Frantzell, S Gupta, et al
Abstract
Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience
in a Raltegravir Intensification Study
V Dahl, S Spudich, E Lee. et al
Abstract
Greater Postprandial LDL-cholesterol Excursions With Low Dose Ritonavir Vs Raltegravir
in HIV-uninfected Adults: a Randomized Study
K Samaras, R Richardson, A Carr
Abstract
Longer Phase I Viral Decay in Treatment-naïve Patients Receiving Raltegravir-based ART:
Preliminary Results from ACTG 5248
A Andrade, S Rosenkranz E Daar, et al
Abstract
Raltegravir Intensification Does Not Reduce Persistent HIV-1 Viremia in Treatment-experienced
Patients
A Wiegand, F Cossarini, C Poethke, et al
Abstract
Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4⁺ T Cell
Response
H Hatano, T Hayes, V Dahl, et al
Abstract
Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation
in Children 6 to 11 Years
S Nachman, E Acosta, P Samson, et al
Abstract

5th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

POSTER
Pharmacokinetics of once daily raltegravir and atazanavir in healthy volunteers
M. Neely, L. Decosterd, A. Fayet, et al
PDF Poster      Abstract

A WEEK-IN-REVIEW-FEATURED REPORT
POSTER
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1
infected patients: final results of the randomized ANRS 138 trial (EASIER)
N. De Castro, J. Braun, I. Charreau, et al
PDF Poster      Abstract

OSTER
Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral
experienced patients
D. Ripamonti, F. Maggiolo, E. Bombana, et al
PDF Poster      Abstract

POSTER
CD4 recovery after switching to raltegravir in a simplified strategy in patients with undetectable
viremia
C. Garrido, J.M. Benito, S. Lozano, et al
PDF Poster      Abstract

POSTER
Raltegravir without a protease inhibitor is highly efficacious in heavily pre-treated individuals
D. Skiest, C. Cohen, D. Barker, et al
PDF Poster      Abstract

POSTER
HIV-DNA load kinetics and therapeutic drug monitoring during raltegravir-based salvage therapy
C. Tommasi, I. Abbate, M. Tempestilli, et al
PDF Poster      Abstract

POSTER
Evolution of 2-LTR episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells
S. Reigadas, M.-L. Andreola, G. Anies, et al
PDF Poster      Abstract

Raltegravir (RAL) intensification does not reduce low-level residual viremia in HIV-1-infected
patients on antiretroviral therapy (ART): results from ACTG A5244
R. Gandhi, S. Zheng, R. Bosch, et al
Abstract

The impact of raltegravir and lopinavir/ritonavir on lipids, adiponectin and peripheral glucose disposal
in HIV negative subjects
P. Randell, A. Jackson, S. Mandalia, et al
Abstract

Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced
patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial
C. Fagard, D. Descamps V. Dubar, et al

Raltegravir QD is as effective and safe as raltegravir BID, with an added benefit in QOL
A. Mena, F. Blanco, M. Córdoba, et al
Abstract

Raltegravir is effective in HIV-1 group O infected patients
A. Depatureaux, M. Leoz, G. Le Moal, et al
Abstract

Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive
HIV-1 infected patients: 144-week data
E. Gotuzzo, B.-Y. Nguyen, M. Markowitz, et al
Abstract

16th CROI

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
96-Week Results from BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART
with Triple-class-resistant HIV
R Steigbigel, D Cooper, J Eron, et al
PDF Poster Abstract
CONFERENCE POSTER
Review of Cancer Incidence in Raltegravir Clinical Trials
D Cooper, R Steigbigel, J Lennnox, et al
PDF Poster Abstract
POSTER
Switch from Enfuvirtide to Raltegravir in Highly Treatment-experienced HIV-1-infected Patients:
A Randomized Open-label Non-inferiority Trial, Easier--ANRS 138
N De Castro, J Braun, I Charreau, et al
PDF Poster Abstract
POSTER
Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenz-based
Combination Therapy in Treatment-naïve HIV-infected Patients
J Lennox, E Dejesus A Lazzarin, et al
PDF Poster Abstract
POSTER
Understanding Decay of Viremia in Patients on Raltegravir
A Spivak, A Reza, M McMahon, A Sedaghat, R Siliciano
PDF Poster Abstract
POSTER
Raltegravir Has No Influence on UGT1A4/2B7 when Using Lamotrigine as a Phenotypic Probe
M Van Luin, A Colbers, E Van Ewijk-Beneken Kolmer, et al
PDF Poster Abstract
POSTER
Immune Activation Markers during Raltegravir Intensification of a HAART Regimen in Subjects
with Persistent HIV-1 Viral Suppression
M Massanella Luna, J Llibre, M Larrousse, et al
PDF Poster Abstract
POSTER
Quasispecies Variant Dynamics during Emergence of Resistance to Raltegravir in HIV-1-infected
Patients
I Malet, O Delelis, C Soulie, et al
PDF Poster Abstract
POSTER
Clonal Analysis of Raltegravir-resistant Patterns Including Mutations at Positions 143 and 155 in the
HIV-1 Integrase
G Anies, D Da Silva, P Recordon-Pinson, et al
PDF Poster Abstract
POSTER
Detection of Low-frequency Mutations Associated with Drug Resistance to Raltegravir before ART
Ji Liu, M Miller, R Danovich, et al
PDF Poster Abstract
POSTER
Raltegravir In Children and Adolescents: The French Expanded Access ProgramPDF Poster
I Thuret, C Tamalet, V Reliquet, et al
PDF Poster Abstract
POSTER
Safety and Efficacy of Raltegravir in Pediatric HIV Infection. Preliminary Analysis from the I
nternational Maternal
Pediatric Adolescent AIDS Clinical Trials Group, P1066
A Wiznia, P Samson, E Acosta, et al
PDF Poster Abstract
Switching from Stable Lopinavir/Ritonavir-based to Raltegravir-based Combination ART
Resulted in a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior
Virologic Efficacy at Week 24
J Eron, J Andrade, R Zajdenverg, et al
Abstract
Identification of Anti-Retroviral Compounds Active on Viruses Resistant to Raltegravir and that
Inhibit HIV-1 Integration despite the Absence of Effect on the Catalytic Activity of Integrase
R Benarous, S Barbey A Simon, et al
Abstract
HIV-1 Mutations at Positions 143, 148, and 155 of Integrase Define Different Genetic Barriers to
Raltegravir Resistance
in vivo
S Fransen, S Gupta, A Frantzell, et al
Abstract
Selective Advantage Curves Explain Evolution of Raltegravir Resistance Genotypes in vivo
R Quercia, E Dam, F Clavel, et al
Abstract
Baseline Variability of HIV-1 Integrase in Multi-experienced Patients Treated with Raltegravir:
A Refined Analysis by Pyrosequencing
F Ceccherini-Silberstein, D Armenia, et al
Abstract
Longitudinal Phenotypic Analysis of Raltegravir-resistant Viruses during Virologic Failure
S Fransen, M Karmochkine, W Huang, et al
Abstract
Evaluation by Allele-specific Real-time Polymerase Chain Reaction of the Presence of Q148H,
Q148R, and N155H Minority Variants at Baseline of a Raltegravir-based Regimen
C Charpentier, C Piketty, P Tisserand, et al
Abstract
The G140S Integrase Mutation from Raltegravir-resistant Patients Rescues HIV-1 Integration |
Defect Induced by the Resistance Mutation Q148H
O Delelis, I Malet, L Na, et al
Abstract
Interaction between HIV-1 Pol-derived Proteins Modulate Viral Fitness without Changes on
Raltegravir Susceptibility
MJ Buzón, J Dalmau, M Puertas, et al
Abs tract
Mutational Mapping on the Integrase-3’-proc-cDNA Complex Suggests 4 Different Mechanisms of
Resistance to Raltegravir and Explains the High-level Resistance of the Most Important Mutants
Selected in vivo
A Vout F Christ, D Vogelaers, et al
Abstract
Transient Increase in Episomal Viral cDNA following Raltegravir Intensification of a Stable HAART
Regimen
M Buzon, J Llibre, J Gatell, et al
Abstract

Ninth International Congress on Drug Therapy in HIV Infection

A WEEK IN REVIEW FEATURED REPORT
Raltegravir therapy in HIV multi-experience patients: safety and efficacy
Meraviglia P, Capetti A, Merli S, et al
Abstract

Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and
liver profile
Blanco F, Arredondo M, Guevara F, et al
Abstract

An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK
Elbasha E, Dunlop W, Chaudhary MA, Kumar RN
Abstract

POSTER
Cost-minimisation analysis of the use of etravirine or raltegravir in treatment-experienced
HIV-1-infected patients
E Smets, S Martin
PDF Poster

Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure
HIV-infected patients: raltegravir, maraviroc, etravirine
Nozza S, Visco F, Soria A. et al
Abstract
Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated
HIV patients (pts)
Gatti F, Matti A, Nasta P, et al
Abstract

Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar
Teppler H, Rockstroh J, Isaacs R, et al
Abstract

Quantitation of raltegravir in human plasma, dried blood spots and peripheral blood mononuclear
cell lysate by means
of LC-MS/MS
ter Heine R, Rosing H, van Gorp ECM,
Abstract

XVII International AIDS Conference

POWERPOINT PRESENTATION
Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive
HIV-1 infected patients: 96-week data
M Markowitz
Poster Presentation
POWERPOINT POSTER PRESENTATION
Trends of integrase inhibitors drug resistance in treatment-naive patients with HIV-1 subtype
C infection in Brazil
C Passaes
Poster Presentation
failure to control viral replication in the brain
D. Armstrong-James
Abstract
High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-
experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial
Y. Yazdanpanah, C. Fagard, D. Descamps, et al
Abstract
RAL-KAL: pharmacokinetics (PK) of coadministered raltegravir (RAL) and lopinavir-ritonavir...
F. Rhame , M. Long , E. Acosta, et al
Abstract
Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically
suppressed patients treated with tipranavir/ritonavir
H. Khanlou, C. Allavena, E. Billaud, et al
Abstract
Clinical experience with raltegravir (MK-0518 or Isentress), with an optimised background r
egimen in highly
treatment-experienced patients
A. Teague, C. Scott, T. Youngstein, et al
Abstract
Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on
an enfuvirtide based regimen
W. Towner, D. Klein, S. Follansbee, et al

15th CROI

POSTER
48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing ART
with Triple-class Resistant HIV
R Steigbigel, P Kumar, J Eron, et al
PDF Poster Abstract
POSTER
48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir in Patients Failing ART with
Triple-class Resistant HIV-1
D Cooper, J Gatell, J Rockstroh, , et al
PDF Poster Abstract
POSTER
Phenotypic Susceptibility in vitro to Raltegravir and Elvitegravir and Polymorphism of the Integrase
Gene of HIV-2 Clinical Isolates
B Roquebert, F Damond, G Collin, G Peytavin
PDF Poster Abstract
More Pronounced Effect of Integrase Inhibitor Raltegravir on Proviral DNA Reduction that other
Antiretroviral Drugs in Patients Achieving Undetectable Viremia
S Arponen, J Benito, S Lozano, et al
Abstract
Outcomes of Patients Switched from Enfuvirtide to Raltegravir within a Virologically Suppressive Regimen
M Harris, G Larsen, J Montaner
Abstract